Fragment deconstruction of small, potent factor Xa inhibitors: exploring the superadditivity energetics of fragment linking in protein-ligand complexes.

Predictable thermodynamic additivity is one of the cornerstones of classical covalent chemistry, allowing accurate calculation of energy terms for complete processes by addition of terms for individual components. However this principle breaks down in complex noncovalent systems, such as biological systems, in which the energetics of individual components are not truly independent of each other. This complicates predicting protein structure and folding and, the focus of this work, the prediction of ligand binding to proteins. Molecular recognition in protein–ligand complexes predominantly occurs through multiple noncovalent interactions, whereas their contribution to the total free-energy of binding (DG) is often unevenly distributed over the contact interface. The identification of ligands as “molecular anchors” for high affinity regions in proteins (“hot spots”) is fundamental for fragment-based drug discovery, 3] indicating the similarity of ligandand protein-centric concepts. Often highaffinity ligands encompass more than one fragment in proximal protein sites; in a few cases, individual fragments in two neighboring sites could be linked to result in high binding affinity. Ideally, the DG of linked fragments should be significantly greater than the sum of DG increments from each fragment. This overproportional increase (“superadditivity”) is attributed to the fact that each fragment loses a significant part of its rigid body rotational and translational entropy upon complex formation. Thus, the sum of DG for two fragments includes two unfavorable rigid body entropy barrier terms, whereas the joined molecule is only affected by one of these terms. Any ligand has to overcome this barrier because of entropy loss upon association to its site. The nonadditivity for DG contributions is defined as linker coefficient E corresponding to the difference between the sums of fragment affinity and the final ligand [Eq. (1)]. DGfinal 1⁄4 DGfrag1 þ DGfrag2 þ DGlink with DGlink 1⁄4 R T ln E ð1Þ

[1]  F. Diederich,et al.  Cation-pi interactions at the active site of factor Xa: dramatic enhancement upon stepwise N-alkylation of ammonium ions. , 2009, Angewandte Chemie.

[2]  François Diederich,et al.  Quantification of cation-pi interactions in protein-ligand complexes: crystal-structure analysis of Factor Xa bound to a quaternary ammonium ion ligand. , 2005, Angewandte Chemie.

[3]  D. A. Dougherty,et al.  Cation-π interactions in structural biology , 1999 .

[4]  S. Brady,et al.  Design and synthesis of a series of potent and orally bioavailable noncovalent thrombin inhibitors that utilize nonbasic groups in the P1 position. , 1998, Journal of medicinal chemistry.

[5]  L. Salonen,et al.  Kation‐π‐Wechselwirkungen im aktiven Zentrum von Faktor Xa: drastische Verstärkung durch stufenweise N‐Alkylierung von Ammoniumionen , 2009 .

[6]  M. Congreve,et al.  Recent developments in fragment-based drug discovery. , 2008, Journal of medicinal chemistry.

[7]  D. Banner,et al.  Quantifizierung von Kation‐π‐Wechselwirkungen in Protein‐Ligand‐Komplexen: Kristallstrukturanalyse eines Komplexes von Faktor Xa und einem quartären Ammonium‐Ion‐Liganden , 2005 .

[8]  Manfred Kansy,et al.  Extending pKa prediction accuracy: high-throughput pKa measurements to understand pKa modulation of new chemical series. , 2010, European journal of medicinal chemistry.

[9]  Hans Matter,et al.  Structural requirements for factor Xa inhibition by 3-oxybenzamides with neutral P1 substituents: combining X-ray crystallography, 3D-QSAR, and tailored scoring functions. , 2005, Journal of medicinal chemistry.

[10]  A. Hillisch,et al.  Entering the era of non-basic p1 site groups: discovery of Xarelto (Rivaroxaban). , 2010, Current topics in medicinal chemistry.

[11]  Marcel L. Verdonk,et al.  The consequences of translational and rotational entropy lost by small molecules on binding to proteins , 2002, J. Comput. Aided Mol. Des..

[12]  Sébastien Maignan,et al.  Molecular structures of human factor Xa complexed with ketopiperazine inhibitors: preference for a neutral group in the S1 pocket. , 2003, Journal of medicinal chemistry.

[13]  P. Hajduk,et al.  Discovering High-Affinity Ligands for Proteins: SAR by NMR , 1996, Science.

[14]  Kerim Babaoglu,et al.  Deconstructing fragment-based inhibitor discovery , 2006, Nature chemical biology.

[15]  Thomas Lampe,et al.  Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor. , 2005, Journal of medicinal chemistry.

[16]  W. Jencks,et al.  Entropic contributions to rate accelerations in enzymic and intramolecular reactions and the chelate effect. , 1971, Proceedings of the National Academy of Sciences of the United States of America.

[17]  Wolfgang Heiden,et al.  Fast generation of molecular surfaces from 3D data fields with an enhanced “marching cube” algorithm , 1993, J. Comput. Chem..

[18]  Stefan Güssregen,et al.  Evidence for C-Cl/C-Br...pi interactions as an important contribution to protein-ligand binding affinity. , 2009, Angewandte Chemie.

[19]  M. Congreve,et al.  Fragment-based lead discovery , 2004, Nature Reviews Drug Discovery.

[20]  V. Mikol,et al.  The use of 3D structural data in the design of specific factor Xa inhibitors. , 2001, Current topics in medicinal chemistry.

[21]  W F van Gunsteren,et al.  Decomposition of the free energy of a system in terms of specific interactions. Implications for theoretical and experimental studies. , 1994, Journal of molecular biology.

[22]  Claudio Luchinat,et al.  Entropic contribution to the linking coefficient in fragment based drug design: a case study. , 2010, Journal of medicinal chemistry.

[23]  Bin Ye,et al.  Crystal structures of two potent nonamidine inhibitors bound to factor Xa. , 2002, Biochemistry.

[24]  D. Cheney,et al.  Factor Xa inhibitors: next-generation antithrombotic agents. , 2010, Journal of medicinal chemistry.

[25]  Jing Zhang,et al.  Design, structure-activity relationships, X-ray crystal structure, and energetic contributions of a critical P1 pharmacophore: 3-chloroindole-7-yl-based factor Xa inhibitors. , 2008, Journal of medicinal chemistry.

[26]  Gennady M Verkhivker,et al.  Unraveling principles of lead discovery: from unfrustrated energy landscapes to novel molecular anchors. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[27]  T. Blundell,et al.  Probing hot spots at protein-ligand binding sites: a fragment-based approach using biophysical methods. , 2006, Journal of medicinal chemistry.

[28]  Emanuele Perola,et al.  An analysis of the binding efficiencies of drugs and their leads in successful drug discovery programs. , 2010, Journal of medicinal chemistry.

[29]  P. Hajduk,et al.  Stromelysin Inhibitors Designed from Weakly Bound Fragments: Effects of Linking and Cooperativity , 1997 .

[30]  G. Klebe,et al.  pH‐Dependent Binding Modes Observed in Trypsin Crystals: Lessons for Structure‐Based Drug Design , 2002 .

[31]  C. Abad-Zapatero,et al.  Ligand efficiency indices for effective drug discovery , 2007, Expert opinion on drug discovery.

[32]  Colin McMartin,et al.  QXP: Powerful, rapid computer algorithms for structure-based drug design , 1997, J. Comput. Aided Mol. Des..

[33]  Beat Ernst,et al.  Drug discovery today. , 2003, Current topics in medicinal chemistry.

[34]  Hans Matter,et al.  Probing the subpockets of factor Xa reveals two binding modes for inhibitors based on a 2-carboxyindole scaffold: a study combining structure-activity relationship and X-ray crystallography. , 2005, Journal of medicinal chemistry.

[35]  K A Dill,et al.  Additivity Principles in Biochemistry* , 1997, The Journal of Biological Chemistry.

[36]  A. Hopkins,et al.  Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.

[37]  Daniel A Erlanson,et al.  Tethering: fragment-based drug discovery. , 2004, Annual review of biophysics and biomolecular structure.

[38]  H. Matter,et al.  Novel factor Xa inhibitors based on a 2-carboxyindole scaffold: SAR of P4 substituents in combination with a neutral P1 ligand. , 2004, Bioorganic & medicinal chemistry letters.

[39]  Christopher W Murray,et al.  Fragment-based lead discovery using X-ray crystallography. , 2005, Journal of medicinal chemistry.

[40]  Gerhard Klebe,et al.  Non-additivity of functional group contributions in protein-ligand binding: a comprehensive study by crystallography and isothermal titration calorimetry. , 2010, Journal of molecular biology.

[41]  S. Barelier,et al.  Fragment-based deconstruction of Bcl-xL inhibitors. , 2010, Journal of medicinal chemistry.

[42]  Loriano Storchi,et al.  New and Original pKa Prediction Method Using Grid Molecular Interaction Fields , 2007, J. Chem. Inf. Model..

[43]  P. Hajduk,et al.  A decade of fragment-based drug design: strategic advances and lessons learned , 2007, Nature Reviews Drug Discovery.